Previous 10 | Next 10 |
Abbott Laboratories ([[ABT]] +0.3%) managed to beat the Street forecasts for Q1 2021 earnings but its revenue failed to do the same as its COVID-19 testing-related sales witnessed a ~8.3% decline sequentially from $2.4B in Q4 2020.The reported revenue from the diagnostic segment which in...
This is not EF Hutton, but it could be more powerful. A picture speaks a thousand words, they say, and the price action of Hologic (NASDAQ: HOLX) tells an important story. The movement tells us where investors perceive value, or the lack of it, and if we pay attention we can...
Danaher Corporation ([[DHR]] +3.7%) has sustained its early gains following an upgrade to its Q1 2021 revenue guidance.The update highlights the company’s leadership in the global market for Covid-19 bioprocessing, noted Keybanc analyst Paul Knight with an outperform rating for th...
Investors seem to be concerned about the revenue and margin pressures that Thermo Fisher will face as pandemic testing demand fades, but the impact isn't likely to be that bad. Bioproduction still offers significant long-term growth, as do areas of instrumentation like cytology, and t...
Hologic (HOLX) has agreed to acquire Mobidiag, a privately held Finnish French commercial company focused on molecular diagnostic tests and instrumentation, for an enterprise value of $795M.The transaction is comprised of ~$714M (€600M) for Mobidiag’s equity, plus net debt of ~$...
-- Transaction Will Accelerate Global Growth of Mobidiag’s Differentiated Molecular Platform, which Offers Ease of Use, Multiplex Capability and Rapid Turnaround Time -- Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, announced today that it has signed a ...
Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the second quarter of fiscal 2021 on Wednesday, April 28, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Easte...
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 6, 2021 – Medical diagnostic and imaging tools have played a critical role in the detection and early diagnosis of diseases such as cancer, which are less treatable in their later ...
This price action in Hologic (NASDAQ: HOLX) can help investors find opportunity, and manage risk. Stock Traders Daily has demonstrated that in this article. Review The plans for HOLX below, and you will see how this works. Keep in mind, this data is current, but it is not re...
The biggest risk with Hologic today is the uncertain path for COVID-19 testing; expanding vaccination rates are driving sharp declines in testing that accounted for almost half of FQ1'21 revenue. Whatever the decline path for COVID-19 testing is, the pandemic drove a significant incre...
News, Short Squeeze, Breakout and More Instantly...
2024-07-30 10:30:04 ET BTIG analyst issues NEUTRAL recommendation for HOLX on July 30, 2024 08:28AM ET. The previous analyst recommendation was Neutral. HOLX was trading at $79.64 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current an...
2024-07-30 09:30:03 ET RBC Capital analyst issues SECTOR PERFORM recommendation for HOLX on July 30, 2024 07:43AM ET. The previous analyst recommendation was Sector Perform. HOLX was trading at $79.64 at issue of the analyst recommendation. The overall analyst consensus ...
– Revenue of $1,011.4 Million, GAAP Diluted EPS of $0.82, and Non-GAAP Diluted EPS of $1.06; All Met or Exceeded Guidance – – Total Company Revenue Growth of 2.7%, or 3.1% in Constant Currency and 5.8% Organically excluding COVID-19; Against Growth of 18.4% in the Prior Y...